Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2010

01.11.2010 | Clinical Study - Patient Study

Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis

verfasst von: Tom Mikkelsen, Joe Anderson, Thomas J. Doyle, David Croteau, Rita Avedissian, Sam Ryu, Lonni Schultz

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

This study sought to establish the recommended phase II dose and efficacy of temozolomide (TMZ) with concurrent radiotherapy in patients with brain metastases. Patients were stratified by prior systemic therapy (≤1 vs. ≥2) and enrolled in cohorts of escalating doses of daily TMZ for 14 days (group A: 75, 95, 115, 135, or 150 mg/m2, group B: 75, 90, 105, 120, or 135 mg/m2). Endpoints included safety and clinical activity. For group A (≤1 prior chemotherapy) no dose limiting toxicity was seen at 75 and 95 mg/m2. Five of eight patients experienced dose limiting toxicities at 115 mg/m2, thus the recommended phase II dose was 95 mg/m2. Arm B (≥2 prior chemotherapy regimens) was closed due to poor enrollment. In the phase II portion, 17 patients in group A were treated. There were 0 patients with complete radiographic response, three with a partial response, ten remained stable, and four demonstrated early progression. The 3 and 6 month progression-free survival (PFS) rates were 41 and 18% with a median PFS time of 2.4 months. Overall survival at 3 and 6 months was 53 and 41%, respectively, with a median survival time of 4.1 months. The maximum tolerated dose of daily TMZ with concurrent WBRT was 95 mg/m2. Despite dose escalation, outcomes did not appear to be improved in the sample treated.
Literatur
1.
Zurück zum Zitat Posner JB (1995) Neurologic complications of cancer. F.A. Davis, Philadelphia Posner JB (1995) Neurologic complications of cancer. F.A. Davis, Philadelphia
2.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
3.
Zurück zum Zitat Wurm R, Roeschel L, Scheffler D (2000) Phase I–II study with continuous dose-escalated 21 day schedule temozolomide in recurrent high-grade glioma. Proc Am Soc Clin Oncol 19:164a Wurm R, Roeschel L, Scheffler D (2000) Phase I–II study with continuous dose-escalated 21 day schedule temozolomide in recurrent high-grade glioma. Proc Am Soc Clin Oncol 19:164a
4.
Zurück zum Zitat Antonadou D, Paraskevaidis M, Sarris G et al (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644–3650CrossRefPubMed Antonadou D, Paraskevaidis M, Sarris G et al (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644–3650CrossRefPubMed
5.
Zurück zum Zitat Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball DL (2004) A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 46:107–111CrossRefPubMed Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball DL (2004) A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 46:107–111CrossRefPubMed
6.
Zurück zum Zitat Ushio Y, Arita N, Hayakawa T et al (1991) Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery 28:201–205CrossRefPubMed Ushio Y, Arita N, Hayakawa T et al (1991) Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery 28:201–205CrossRefPubMed
7.
Zurück zum Zitat Verger E, Gil M, Yaya R et al (2005) Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61:185–191PubMed Verger E, Gil M, Yaya R et al (2005) Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61:185–191PubMed
8.
Zurück zum Zitat Kim DY, Lee KW, Yun T et al (2005) Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer. Oncol Rep 14:207–211PubMed Kim DY, Lee KW, Yun T et al (2005) Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer. Oncol Rep 14:207–211PubMed
9.
Zurück zum Zitat Kouvaris JR, Miliadou A, Kouloulias VE et al (2007) Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie 30:361–366CrossRefPubMed Kouvaris JR, Miliadou A, Kouloulias VE et al (2007) Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie 30:361–366CrossRefPubMed
10.
Zurück zum Zitat Weller M (2007) Radiochemotherapy for brain metastasis: how to define a role for temozolomide. Onkologie 30:350–351CrossRefPubMed Weller M (2007) Radiochemotherapy for brain metastasis: how to define a role for temozolomide. Onkologie 30:350–351CrossRefPubMed
11.
Zurück zum Zitat Addeo R, Caraglia M, Faiola V et al (2007) Concomitant treatment of brain metastasis with whole brain radiotherapy (WBRT), temozolomide (TMZ) is active, improves quality of life. BMC Cancer 7:18CrossRefPubMed Addeo R, Caraglia M, Faiola V et al (2007) Concomitant treatment of brain metastasis with whole brain radiotherapy (WBRT), temozolomide (TMZ) is active, improves quality of life. BMC Cancer 7:18CrossRefPubMed
Metadaten
Titel
Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis
verfasst von
Tom Mikkelsen
Joe Anderson
Thomas J. Doyle
David Croteau
Rita Avedissian
Sam Ryu
Lonni Schultz
Publikationsdatum
01.11.2010
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2010
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-010-0187-8

Weitere Artikel der Ausgabe 2/2010

Journal of Neuro-Oncology 2/2010 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.